RESUMEN
OBJECTIVE: This study evaluated Helicobacter pylori eradication therapy in terms of symptomatic response in patients with functional dyspepsia. On the other hand, we analyzed the importance of histologic findings as a predictor of treatment response. In particular, we studied whether antral gastritis (which is associated with peptic ulcer) may predict a greater symptomatic response to Helicobacter pylori eradication in functional dyspepsia. PATIENTS AND METHODS: This prospective, randomized, single-center trial included 48 patients with functional dyspepsia and Helicobacter pylori infection (27 women and 21 men, mean age 37 +/- 13.5 years). Twenty-seven patients received a 10-day course of rabeprazole, amoxicillin, and clarithromycin (eradication group), followed by 20 mg of rabeprazole for 3 months. Twenty-one patients received 20 mg of rabeprazole for 3 months (control group). Patients were followed up over a 1-year period. All patients completed the Dyspepsia-Related Health Scale Questionnaire, which studies four dimensions: pain intensity, pain disability, non-pain symptoms, and satisfaction with dyspepsia-related health. RESULTS: There was significant symptomatic improvement (p < 0.002) after 6 and 12 months, which was similar with both treatments. In the multivariate analyses, eradication therapy and less severe symptoms before treatment were the only independent factors. The symptomatic response to Helicobacter pylori eradication after 6 months was significantly greater as compared to control therapy (p = 0.01) in patients with antral gastritis and in the non-pain symptoms dimension of the questionnaire. CONCLUSIONS: Both treatments proved to be clinically beneficial in patients with functional dyspepsia. We observed a tendency to greater symptomatic benefit with Helicobacter pylori eradication therapy when compared to control treatment in patients with functional dyspepsia and in a population with a high prevalence of this infection. There is a tendency to symptomatic benefit with Helicobacter pylori eradication therapy in patients with antral gastritis.
Asunto(s)
2-Piridinilmetilsulfinilbencimidazoles/uso terapéutico , Amoxicilina/uso terapéutico , Antibacterianos/uso terapéutico , Antiulcerosos/uso terapéutico , Claritromicina/uso terapéutico , Dispepsia/tratamiento farmacológico , Dispepsia/etiología , Infecciones por Helicobacter/complicaciones , Infecciones por Helicobacter/tratamiento farmacológico , Helicobacter pylori , Adolescente , Adulto , Anciano , Femenino , Gastritis/tratamiento farmacológico , Gastritis/microbiología , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Rabeprazol , Adulto JovenRESUMEN
Objetivo: este estudio ha tenido un doble objetivo: por unlado, evaluar el efecto del tratamiento erradicador para Helicobacterpylori en la respuesta sintomática de pacientes diagnosticadosde dispepsia funcional y, por otro, determinar si los hallazgoshistológicos podían servir como predictor de la efectividad dela terapia. En particular, se trató de averiguar si la presencia degastritis antral (la que se asocia a la enfermedad ulcerosa péptica)podría predecir una mayor respuesta sintomática al tratamientoerradicador en los pacientes con dispepsia funcional e infecciónpor Helicobacter pylori.Pacientes y métodos: estudio prospectivo, monocéntrico yaleatorizado, que incluyó a 48 pacientes con dispepsia funcional einfección por Helicobacter pylori (27 mujeres y 21 hombres, conedad media de 37 ± 13,5 años). Veintisiete pacientes recibieronel tratamiento erradicador (rabeprazol, claritromicina y amoxicilinadurante 10 días, seguido de 20 mg/día de rabeprazol 3 meses)y 21 el tratamiento control (20 mg/día de rabeprazol 3 meses).Los pacientes fueron seguidos durante un año. Todos rellenaronel Cuestionario de calidad de vida asociada a dispepsia, queevalúa cuatro apartados: intensidad de los síntomas habituales, intensidaddel dolor de estómago, incapacidad debida al dolor y satisfaccióncon la salud.Resultados: existió una mejoría significativa (p < 0,002) enlos síntomas de los pacientes, tanto a los 6 como a los 12 mesestras el inicio del tratamiento, que además fue común a las dospautas de tratamiento. En el análisis de regresión lineal múltiple,los efectos del tratamiento erradicador y de tener una sintomatologíamenos intensa antes de recibir el tratamiento, fueron los dosúnicos factores independientes de forma significativa. La respuestaal tratamiento erradicador a los 6 meses fue significativamentemayor que con el tratamiento control (p = 0,01) en los pacientescon gastritis de predominio antral y en el apartado concreto de lossíntomas habituales. Conclusiones: ambos tratamientos producen una mejoríasintomática significativa en los pacientes con dispepsia funcional.Se observa una tendencia hacia un beneficio sintomático mayorcon el tratamiento erradicador respecto al control en pacientescon dispepsia funcional y en un medio con elevada prevalencia deinfección por Helicobacter pylori. Existe una tendencia hacia lamejoría sintomática con el tratamiento erradicador en los pacientesque tienen una gastritis de predominio antral
Objective: this study evaluated Helicobacter pylori eradicationtherapy in terms of symptomatic response in patients withfunctional dyspepsia. On the other hand, we analyzed the importanceof histologic findings as a predictor of treatment response.In particular, we studied whether antral gastritis (which is associatedwith peptic ulcer) may predict a greater symptomatic responseto Helicobacter pylori eradication in functional dyspepsia.Patients and methods: this prospective, randomized, single-center trial included 48 patients with functional dyspepsiaand Helicobacter pylori infection (27 women and 21 men,mean age 37 ± 13.5 years). Twenty-seven patients received a10-day course of rabeprazole, amoxicillin, and clarithromycin(eradication group), followed by 20 mg of rabeprazole for 3months. Twenty-one patients received 20 mg of rabeprazole for3 months (control group). Patients were followed up over a 1-year period. All patients completed the Dyspepsia-RelatedHealth Scale Questionnaire, which studies four dimensions:pain intensity, pain disability, non-pain symptoms, and satisfactionwith dyspepsia-related health.Results: there was significant symptomatic improvement (p <0.002) after 6 and 12 months, which was similar with both treatments.In the multivariate analyses, eradication therapy and lesssevere symptoms before treatment were the only independent factors.The symptomatic response to Helicobacter pylori eradicationafter 6 months was significantly greater as compared to controltherapy (p = 0.01) in patients with antral gastritis and in thenon-pain symptoms dimension of the questionnaire.Conclusions: both treatments proved to be clinically beneficialin patients with functional dyspepsia. We observed a tendencyto greater symptomatic benefit with Helicobacter pylori eradicationtherapy when compared to control treatment in patients withfunctional dyspepsia and in a population with a high prevalence of this infection. There is a tendency to symptomatic benefit withHelicobacter pylori eradication therapy in patients with antralgastritis
Asunto(s)
Humanos , Masculino , Femenino , Adolescente , Adulto , Persona de Mediana Edad , Anciano , Amoxicilina/uso terapéutico , Antibacterianos/uso terapéutico , Antiulcerosos/uso terapéutico , Claritromicina/uso terapéutico , Dispepsia/tratamiento farmacológico , Dispepsia/etiología , Infecciones por Helicobacter/complicaciones , Infecciones por Helicobacter/tratamiento farmacológico , Helicobacter pylori , Gastritis/tratamiento farmacológico , Gastritis/microbiología , Estudios ProspectivosRESUMEN
INTRODUCTION: Aneuploidy has been observed in 6-27% of lesions known to be precursors of colorectal cancer, such as adenomas or ulcerative colitis. It has been suggested that aneuploidy may predispose to malignancy in these cases. However, its role in the adenoma-carcinoma sequence has not been definitely established. The objective of this study was to assess the incidence of aneuploidy in colon adenomas, as well as to study its possible role in the adenoma-carcinoma sequence. MATERIAL AND METHODS: The study was performed on a series of 57 large bowel adenomas measuring 10 mm or more, collected from 54 consecutive patients. All specimens were obtained either by endoscopic or by surgical resection. There were 49 adenomas with low-grade dysplasia, two with high-grade dysplasia, two intramucous carcinomas, and four microinvasive carcinomas. A flow cytometric DNA analysis was performed in fresh specimens following Vindelov's method. RESULTS: Aneuploid DNA was detected in five out of 49 low-grade dysplasia adenomas (10%), in all four high-grade dysplasia adenomas or intramucous carcinomas (100%), and in three out of four microinvasive carcinomas (75%). The association between aneuploidy and high-grade dysplasia adenomas, intramucous, or microinvasive carcinoma was statistically significant (p < 0.001). No association was found between aneuploidy and any of the following features: age, gender, clinical symptoms of patients, and size or location of adenomas. CONCLUSIONS: The incidence of aneuploidy in this series was 10% in low-grade dysplasia adenomas, and 87% in high-grade dysplasia adenomas or carcinomas, and this difference was statistically significant. These findings suggest that aneuploidy may play a role in the adenoma-carcinoma sequence.
Asunto(s)
Adenoma/genética , Aneuploidia , Neoplasias Colorrectales/genética , Lesiones Precancerosas/genética , Adenoma/patología , Anciano , Neoplasias Colorrectales/patología , ADN/análisis , Femenino , Humanos , Masculino , Persona de Mediana Edad , Lesiones Precancerosas/patologíaRESUMEN
Introducción: en patología benigna de intestino grueso precursora del cáncer colorrectal, como adenomas o colitis ulcerosa, se ha observado aneuploidía en el 6-27% de los casos y se ha sugerido que su presencia predispone al desarrollo de malignidad. Sin embargo, su papel en la secuencia adenoma-carcinoma no se ha demostrado de forma concluyente. El objetivo de nuestro trabajo fue valorar la incidencia de aneuploidía en adenomas colónicos,con y sin signos de malignidad, y estudiar su posible papel en la secuencia adenoma-carcinoma. Material y métodos: el estudio se realizó en una serie de 57 adenomas de intestino grueso, de 10 o más milímetros, recogidos de forma consecutiva de 54 pacientes. Las piezas se obtuvieron en todos los casos mediante resección endoscópica o quirúrgica. En 49 casos se trataba de adenomas con displasia de bajo grado, en doscasos de adenomas con displasia de alto grado, dos adenocarcinomas intramucosos y en otros cuatro de adenocarcinomas microinvasivos. El estudio del ADN se realizó en la pieza operatoria en fresco mediante citometría de flujo utilizado el método de Vindelov.Resultados: se detectó ADN aneuploide en cinco de los 49adenomas con displasia de bajo grado (10%), en los cuatro adenomas con displasia de alto grado o adenocarcinomas intramucosos (100%) y en tres de los cuatro adenocarcinomas microinvasivos (75%). Se observó asociación significativa entre el hallazgos deaneuploidía y displasia de alto grado, adenocarcinoma intramucoso o microinvasivo (p < 0,001). No se apreció asociación entre la existencia de aneuploidía y la edad de los pacientes, sexo, sintomatología clínica, tamaño ni localización de los adenomas. Conclusiones: en adenomas colónicos la incidencia de aneuploidía fue del 10% cuando se trataba de adenomas con displasia de bajo grado y del 87% cuando presentaban displasia de alto grado o adenocarcinoma siendo la diferencia estadísticamente significativa. Estos hallazgos sugieren que la aneuploidía juega un papel en la secuencia adenoma-carcinoma
Introduction: aneuploidy has been observed in 6-27% of lesions known to be precursors of colorectal cancer, such as adenomas or ulcerative colitis. It has been suggested that aneuploidy may predispose to malignancy in these cases. However, its role in the adenoma-carcinoma sequence has not been definitely established.The objective of this study was to assess the incidence of aneuploidy in colon adenomas, as well as to study its possible role in the adenoma-carcinoma sequence. Material and methods: the study was performed on a series of 57 large bowel adenomas measuring 10 mm or more, collected from 54 consecutive patients. All specimens were obtained either by endoscopic or by surgical resection. There were 49 adenomas with low-grade dysplasia, two with high-grade dysplasia, two intramucous carcinomas, and four microinvasive carcinomas. A flow cytometric DNA analysis was performed in fresh specimens following Vindelov´s method. Results: aneuploid DNA was detected in five out of 49 lowgrade dysplasia adenomas (10%), in all four high-grade dysplasia adenomas or intramucous carcinomas (100%), and in three out of four microinvasive carcinomas (75%). The association between aneuploidy and high-grade dysplasia adenomas, intramucous, or microinvasive carcinoma was statistically significant (p < 0.001). No association was found between aneuploidy and any of the following features: age, gender, clinical symptoms of patients, and size or location of adenomas. Conclusions: the incidence of aneuploidy in this series was 10% in low-grade dysplasia adenomas, and 87% in high-grade dysplasia adenomas or carcinomas, and this difference was statistically significant. These findings suggest that aneuploidy may play a role in the adenoma-carcinoma sequence
Asunto(s)
Anciano , Humanos , Adenoma/genética , Aneuploidia , Lesiones Precancerosas/genética , Neoplasias Colorrectales/genética , Adenoma/patología , ADN/análisis , Lesiones Precancerosas/patología , Neoplasias Colorrectales/patologíaRESUMEN
INTRODUCTION: Infection with the parasite Anisakis simplex is common in Japan and northern European countries. The number of reported cases in Spain has increased since the first description in 1991. The aim of the present study was to evaluate the incidence, clinical patterns, histopathological lesions, treatment, and outcome of Anisakis simplex infection in our environment. MATERIAL AND METHOD: Cases of gastrointestinal anisakiasis diagnosed in our center from December 1999 to January 2002 were studied. Only patients with detection of the parasite in oral endoscopy or the surgical specimen and those with elevated levels of specific IgE to Anisakis simplex, a clinical picture compatible with anisakiasis, or a history of raw fish intake were included. Epidemiological, clinical and laboratory data, as well as diagnostic, histopathologic and therapeutic features, and outcome in these patients were recorded. RESULTS: Twenty-five cases of gastrointestinal anisakiasis were diagnosed during the study period, representing an incidence of 3.87 cases per 100 000 inhabitants/year. All the patients had ingested raw anchovies. Two groups were observed. The first group was composed of 10 patients with a gastric form of the infection, in which the main symptom was epigastralgia (90%). Oral endoscopy was performed in all patients and the parasite was detected in five (50%). The second group was composed of 15 patients with intestinal involvement in which the main manifestations were symptoms mimicking appendicitis (80%). The most frequent finding of laparotomy and/or imaging tests (abdominal ultrasonography, intestinal transit, abdominal CAT) was terminal ileitis (80%). Seven patients underwent surgery: intestinal resection was performed in four with detection of Anisakis simplex in three. Eosinophilic infiltration was found in all surgical specimens. Treatment was symptomatic in most of the patients and outcome was favorable in all. CONCLUSIONS: Infection with Anisakis simplex should be investigated in patients with abdominal pain after intake of raw fish, ileitis of unclear origin, or eosinophilic gastroenteritis.